Weeks af­ter drop­ping big re­sponse da­ta, Am­gen lines up pri­or­i­ty re­view for KRAS hope­ful so­tora­sib in NSCLC

Am­gen is look­ing to go where no oth­er drug­mak­er has gone be­fore with the KRAS in­hibitor so­tora­sib, which post­ed big Phase II lung can­cer re­sponse …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.